FOLH1 and prostate carcinoma: Using aqueous two-phase methods, they successfully isolated PSMA-positive microparticles showing an extremely particular specificity for prostate cancer, allowing it to be differentiated from benign prostate hyperplasia with a sensitivity and specificity of about 91.7%.